Argyle Capital Management Inc. Sells 19,917 Shares of Pfizer Inc. (NYSE:PFE)

Argyle Capital Management Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 14.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 117,283 shares of the biopharmaceutical company’s stock after selling 19,917 shares during the period. Pfizer makes up approximately 1.4% of Argyle Capital Management Inc.’s portfolio, making the stock its 24th biggest holding. Argyle Capital Management Inc.’s holdings in Pfizer were worth $3,377,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Briaud Financial Planning Inc bought a new position in shares of Pfizer in the third quarter worth approximately $30,000. GoalVest Advisory LLC increased its position in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new position in shares of Pfizer in the third quarter worth approximately $34,000. VisionPoint Advisory Group LLC boosted its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new stake in Pfizer in the fourth quarter worth approximately $36,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Trading Up 0.6 %

Shares of NYSE:PFE traded up $0.14 during trading on Friday, reaching $25.40. 46,526,457 shares of the company traded hands, compared to its average volume of 34,120,812. The business’s fifty day moving average is $26.96 and its 200-day moving average is $28.36. The firm has a market capitalization of $143.83 billion, a price-to-earnings ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the previous year, the company earned $1.14 earnings per share. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.61%. Pfizer’s dividend payout ratio is currently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.